IL4 and obesity due to melanocortin 4 receptor deficiency: Thus, it is plausible that novel pharmacological intervention in the IL-4/IL4Rα axis function, in both hematopoietic as well as non-hematopoietic cells, would provide novel approaches to dampen high dietary fructose-driven metabolic harm associated with obesity.